ESMO CPG express update on the management of metastatic pancreatic cancer

ESMO Clinical Practice Guideline express update on the management of metastatic pancreatic cancer - European Society For Medical Oncology (ESMO)

This ESMO Clinical Practice Guideline update addresses developments in the management of metastatic pancreatic cancer.

It has been issued following the approval of first-line nanoliposomal irinotecan (NALIRIFOX regimen).

Updated first- and second-line treatment recommendations are provided.

An updated management algorithm for metastatic pancreatic cancer is also included.


Read full Guideline